V
81.06
-6.23 (-7.14%)
| Penutupan Terdahulu | 87.29 |
| Buka | 86.20 |
| Jumlah Dagangan | 1,227,274 |
| Purata Dagangan (3B) | 1,149,036 |
| Modal Pasaran | 10,103,074,816 |
| Harga / Buku (P/B) | 3.14 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 25 Feb 2025 - 3 Mar 2025 |
| EPS Cair (TTM) | -4.60 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.82% |
| Nisbah Semasa (MRQ) | 17.88 |
| Aliran Tunai Operasi (OCF TTM) | -470.04 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -404.95 M |
| Pulangan Atas Aset (ROA TTM) | -14.94% |
| Pulangan Atas Ekuiti (ROE TTM) | -21.06% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Vaxcyte, Inc. | Menurun | Menaik |
AISkor Stockmoo
1.8
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 1.75 |
|
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Orang Dalam | 0.50% |
| % Dimiliki oleh Institusi | 112.01% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Darwin Global Management, Ltd. | 30 Sep 2024 | 2,198,187 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 140.00 (Needham, 72.71%) | Beli |
| Median | 137.50 (69.63%) | |
| Rendah | 135.00 (Goldman Sachs, 66.54%) | Beli |
| Purata | 137.50 (69.63%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 95.30 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Goldman Sachs | 20 Dec 2024 | 135.00 (66.54%) | Beli | 86.53 |
| Needham | 06 Nov 2024 | 140.00 (72.71%) | Beli | 104.07 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 03 Dec 2024 | Pengumuman | Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants |
| 12 Nov 2024 | Pengumuman | Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs |
| 05 Nov 2024 | Pengumuman | Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |